A Phase 3 interventional study of Ropivacaine and dexamethasone injection solution and Sodium Chloride 0.9% Injection Solution in Lumbago, sponsored by Elsan. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Elsan · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Low Back Pain with a site in France — 30 open to participants now, 33 under way, 5 of them phase 3. Low Back Pain · France.
Among the 114 studies in Low Back Pain with a site in France, this one is the 53rd largest by planned enrollment of the 79 interventional ones that give a count, is one of 11 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 11 of the 32 other live ones, and was the 91st registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →30 of the 114 studies in Low Back Pain with a site in France are open now. Recruiting first, the newest first:
Clinique de la Côte d'Emeraude · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–55
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 11 · Phase 4 4
First in 2003; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 82 across the 79 interventional studies, 80 across the 35 observational. Of the 69 that completed or were terminated, 4 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 114 have an industry lead sponsor. The 10 most frequent:
Elsan is the lead sponsor of 68 studies on the registry; 35 are open to participants now.
Elsan has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
9 of the studies in Low Back Pain with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04075539Phase 3Assistance Publique - Hôpitaux de ParisHome-based Cycling for People With Lumbar Spinal Stenosis | 2027-06 |
| NCT05511012University Hospital, BrestDoes the Therapist's Assessment of Movement Control in Low Back Pain Patients Correspond to an Objective Kinematic Modification | 2026-12-15 |
| NCT06347328Centre Hospitalier Universitaire de NiceThe Benefits of Posterior Joint Infiltration in Chronic Low Back Pain | 2027-01 |
| NCT05231265Centre Hospitalier Universitaire de NīmesEffect of Lumbar Surgery on Complexity During a Walking Task in Chronic Low Back Pain | 2027-04 |
| NCT07375914Assistance Publique - Hôpitaux de ParisComprehensive Biopsychosocial Approach for Acute Low Back Pain Management in the Emergency Department: a Stepped-wedge Cluster-randomized Clinical Trial | 2027-04-14 |
Add all 9 to your calendar (.ics) → With an account.
Among the 114 studies in Low Back Pain with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study concerns the treatment of recent lumbago and aims to evaluate the efficacy of an anesthetic block of the erector spinae muscles combining ropivacaine and dexamethasone. This treatment is routinely used in several institutions in France, but has never been the subject of a randomized placebo-controlled study to assess its efficacy at D4 of treatment.
The BLOCLOMB comparative, randomized, double-blind study aims to validate the efficacy, over the first 4 days, of anesthetic blocks of the erector spinae muscles, during recent lumbago, on the pain of muscular contractures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of "red flag" (non-disc lumbago):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental treatment consists in one single interlaminal injection of 2x20ml Ropivacaine (0.375%) distributed over the L4-L5 (Lumbar vertebrae 4 and 5) and L5-S1 (Lumbar vertebrae 5 and sacrum 1) levels on both sides, combined with 2x4ml Dexamethasone soluble (i.e. 2x1ml). This dose and method of administration are those required for locoregional anesthesia.
Drug: Ropivacaine and dexamethasone injection solution
The placebo treatment consists in one single interlaminal injection of 2x20ml sodium chloride 0.9% distributed over the L4-L5 and L5-S1 levels on both sides.
Drug: Sodium Chloride 0.9% Injection Solution
Drug pages: RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Injection of Ropivacaine and dexamethasone
Injection of sodium chloride 0.9%
Lumbar pain in activity
Area under the curve of lumbar pain in activity measured by the patient on a numeric scale (from 0=no pain, and 10=unbearable pain)
Time frame: At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day2-Day3-Day4. (Hour 0=injection time, Day 1=One day after injection time)
Consumption of concomitant lumbago treatments
Recording of analgesics and NSAIDs, physiotherapy, manipulations, open surgery, etc
Time frame: From Day 0 (day of injection) to Day 4
Lumbar pain at rest
Lumbar pain measured by the patient on a numeric scale
Time frame: Day 4
Lumbar pain in activity
Lumbar pain measured by the patient on a numeric scale
Time frame: Day 4
Lumbar pain at rest
Area under the curve of lumbar pain at rest measured by the patient on a numeric scale
Time frame: At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day 2-Day 3-Day 4-Day 7-Day 14-Day 21-Day 28
Lumbar Pain < 3
Percentage of patients with pain \< 3 (measured by the patient on a numeric scale, at rest)
Time frame: Day 4
Algofunctional index
Oswestry questionnaire: comprises 10 questions on pain, personal care, load-bearing, walking, sitting, standing, sleep, sex life, social life and travel. Each question offers 6 answers, with a score from 0 to 6, which the patient must choose; a score of 0 corresponds to normal function, and a score of 6 to severely impaired function. The score obtained is multiplied by 2 to obtain a percentage of disability, with 0% for no disability, and 100% for the greatest disability.
Time frame: Day 0, Day 4 and Day 28
Duration of the interruption of current activities
Number of days without current activities
Time frame: 28 days
Duration of the interruption of work
Number of days of sick leave
Time frame: 28 days
Complications
Complications will focus on the following adverse events: 1. injection-site hematoma, nerve damage, limb pain, convulsions, respiratory discomfort, bradycardia, severe vagal malaise 2. fall, iatrogenic infection 3. new lumbago, sciatica or complicated crural neuralgia (neurological deficit, cauda equina syndrome) 4. allergy, digestive complication, renal complication 5. other to be specified
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.
Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ropivacaine · Dexamethasone
Elsan